相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Role of Fc-FcγR interactions in the antitumor activity of therapeutic antibodies
Bryan C. Barnhart et al.
IMMUNOLOGY AND CELL BIOLOGY (2017)
Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin
Peter Jones et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
EPIDERMAL GROWTH FACTOR IMPROVES INTESTINAL INTEGRITY AND SURVIVAL IN MURINE SEPSIS FOLLOWING CHRONIC ALCOHOL INGESTION
Nathan J. Klingensmith et al.
SHOCK (2017)
Recent progress in the understanding of complement activation and its role in tumor growth and anti-tumor therapy
Xiang-Yu Liu et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Melanoma antigens and related immunological markers
Jacob Pitcovski et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Tyrosine kinase/phosphatase inhibitors decrease dengue virus production in HepG2 cells
Thawornchai Limjindaporn et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Immune Checkpoint Inhibitors: An Introduction to the Next-Generation Cancer Immunotherapy
Lucy Lee et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
ErbB2 Blockade with Herceptin (Trastuzumab) Enhances Peripheral Nerve Regeneration after Repair of Acute or Chronic Peripheral Nerve Injury
J. Michael Hendry et al.
ANNALS OF NEUROLOGY (2016)
Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial
R. Bissonnette et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
The Basis of Oncoimmunology
A. Karolina Palucka et al.
CELL (2016)
Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients
Sumita Trivedi et al.
CLINICAL CANCER RESEARCH (2016)
Ipilimumab and Bevacizumab in Glioblastoma
T. Carter et al.
CLINICAL ONCOLOGY (2016)
Anti-inflammatory effect of topical administration of tofacitinib on corneal inflammation
Tohru Sakimoto et al.
EXPERIMENTAL EYE RESEARCH (2016)
Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment
Keith T. Schmidt et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma
Francesco Sabbatino et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Targeting natural killer cells in cancer immunotherapy
Camille Guillerey et al.
NATURE IMMUNOLOGY (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors
Helena Escuin-Ordinas et al.
NATURE COMMUNICATIONS (2016)
Opposing Regulation of the EGF Receptor: A Molecular Switch Controlling Cytomegalovirus Latency and Replication
Jason Buehler et al.
PLOS PATHOGENS (2016)
Impairment of cocaine-mediated behaviours in mice by clinically relevant Ras-ERK inhibitors
Alessandro Papale et al.
ELIFE (2016)
Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma
Francesco Sabbatino et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma
Hirokazu Matsushita et al.
CANCER IMMUNOLOGY RESEARCH (2016)
VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma
Xinqi Wu et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Immunological Mechanisms Underneath the Efficacy of Cancer Therapy
Lorenzo Galluzzi et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Entry inhibitors: New advances in HCV treatment
Xi-Jing Qian et al.
EMERGING MICROBES & INFECTIONS (2016)
RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers
Hidetoshi Sumimoto et al.
PLOS ONE (2016)
Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs
Panagiota Papanagnou et al.
PHARMACEUTICALS (2016)
Inhibitors of cellular kinases with broad-spectrum antiviral activity for hemorrhagic fever viruses
Emma L. Mohr et al.
ANTIVIRAL RESEARCH (2015)
Epidermal growth factor receptor - inhibition (EGFR-I) in the treatment of neuropathic pain
C. Kersten et al.
BRITISH JOURNAL OF ANAESTHESIA (2015)
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
Lorenzo Galluzzi et al.
CANCER CELL (2015)
Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer
Keiichi Ota et al.
CLINICAL CANCER RESEARCH (2015)
Recent developments and future challenges in immune checkpoint inhibitory cancer treatment
Bas D. Koster et al.
CURRENT OPINION IN ONCOLOGY (2015)
Drug repositioning and repurposing: terminology and definitions in literature
Joris Langedijk et al.
DRUG DISCOVERY TODAY (2015)
EGFR kinase activity is required for TLR4 signaling and the septic shock response
Saurabh Chattopadhyay et al.
EMBO REPORTS (2015)
Emerging Functions of Amphiregulin in Orchestrating Immunity, Inflammation, and Tissue Repair
Dietmar M. W. Zaiss et al.
IMMUNITY (2015)
Tumor neoantigens: building a framework for personalized cancer immunotherapy
Matthew M. Gubin et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Basophil-Derived Amphiregulin Is Essential for UVB Irradiation-Induced Immune Suppression
Chantal Meulenbroeks et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
Nan Chen et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
TGF-β and EGF induced HLA-I downregulation is associated with epithelial-mesenchymal transition (EMT) through upregulation of snail in prostate cancer cells
Xiao-Hui Chen et al.
MOLECULAR IMMUNOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells
Riki Okita et al.
PLOS ONE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Kim C. Ohaegbulam et al.
TRENDS IN MOLECULAR MEDICINE (2015)
The activation of EGFR promotes myocardial tumor necrosis factor-α production and cardiac failure in endotoxemia
Xuegang Sun et al.
ONCOTARGET (2015)
Modulation of influenza vaccine immune responses using an epidermal growth factor receptor kinase inhibitor
Joanna A. Pulit-Penaloza et al.
SCIENTIFIC REPORTS (2015)
Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinoma
Takumi Kumai et al.
SCIENTIFIC REPORTS (2015)
BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma
Sherille D. Bradley et al.
CANCER IMMUNOLOGY RESEARCH (2015)
STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients
Raghvendra M. Srivastava et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Immune biomarkers of anti-EGFR monoclonal antibody therapy
S. Trivedi et al.
ANNALS OF ONCOLOGY (2015)
Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C
Fei Xiao et al.
GUT (2015)
IgG1 anti-epidermal growth factor receptor antibodies induce CD8-dependent antitumor activity
Jan Kubach et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Molecular and cellular insights into T cell exhaustion
E. John Wherry et al.
NATURE REVIEWS IMMUNOLOGY (2015)
EGFR activation suppresses respiratory virus-induced IRF1-dependent CXCL10 production
April Kalinowski et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2014)
Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms
Sariah Liu et al.
CANCER TREATMENT REVIEWS (2014)
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Mohammad Atefi et al.
CLINICAL CANCER RESEARCH (2014)
Targeted therapy-induced diarrhea: A review of the literature
M. A. Pessi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
Combining Targeted Therapy With Immunotherapy in BRAF-Mutant Melanoma: Promise and Challenges
Siwen Hu-Lieskovan et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
A new link between diabetes and cancer: enhanced WNT/β-catenin signaling by high glucose
Custodia Garcia-Jimenez et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2014)
EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation
Hanane Lanaya et al.
NATURE CELL BIOLOGY (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The ErbB/HER family of protein-tyrosine kinases and cancer
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2014)
Immunological Visibility: Posttranscriptional Regulation of Human NKG2D Ligands by the EGF Receptor Pathway
Pierre Vantourout et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer
Jennifer A. Wargo et al.
CANCER DISCOVERY (2014)
Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab
Jianda Yuan et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
CANCER IMMUNOLOGY RESEARCH (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome
Mizuki Nishinol et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Control of the immune response by pro-angiogenic factors
Thibault Voron et al.
FRONTIERS IN ONCOLOGY (2014)
EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy
T. Kumai et al.
BRITISH JOURNAL OF CANCER (2013)
The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
Xiaofeng Jiang et al.
CLINICAL CANCER RESEARCH (2013)
Effective Anti-Neu-Initiated Antitumor Responses Require the Complex Role of CD4+ T Cells
Eric D. Mortenson et al.
CLINICAL CANCER RESEARCH (2013)
Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients
Raghvendra M. Srivastava et al.
CLINICAL CANCER RESEARCH (2013)
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
Dennie T. Frederick et al.
CLINICAL CANCER RESEARCH (2013)
Epidermal Growth Factor Receptor Signaling Impairs the Antiviral Activity of Interferon-Alpha
Joachim Lupberger et al.
HEPATOLOGY (2013)
Amphiregulin Enhances Regulatory T Cell-Suppressive Function via the Epidermal Growth Factor Receptor
Dietmar M. W. Zaiss et al.
IMMUNITY (2013)
Respiratory virus-induced EGFR activation suppresses IRF1-dependent interferon ℷ and antiviral defense in airway epithelium
Iris F. Ueki et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
The MAPK Pathway Is a Predominant Regulator of HLA-A Expression in Esophageal and Gastric Cancer
Kousaku Mimura et al.
JOURNAL OF IMMUNOLOGY (2013)
MHC Class I Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor Cells
Patrizia Leone et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
Antoni Ribas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Viral antigen density and confinement time regulate the reactivity pattern of CD4 T-cell responses to vaccinia virus infection
Vijay Vanguri et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Genetic Ablation of Epidermal EGFR Reveals the Dynamic Origin of Adverse Effects of Anti-EGFR Therapy
Francesca Mascia et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Epidermal EGFR Controls Cutaneous Host Defense and Prevents Inflammation
Beate M. Lichtenberger et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Esra A. Akbay et al.
CANCER DISCOVERY (2013)
Adipose tissue immunity and cancer
Victoria Catalan et al.
FRONTIERS IN PHYSIOLOGY (2013)
VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer
Magali Terme et al.
ONCOIMMUNOLOGY (2013)
Vemurafenib enhances MHC induction in BRAFV600E homozygous melanoma cells
Bishu Sapkota et al.
ONCOIMMUNOLOGY (2013)
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
James S. Wilmott et al.
CLINICAL CANCER RESEARCH (2012)
Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma
Jahan S. Khalili et al.
CLINICAL CANCER RESEARCH (2012)
Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy
Benedetto Farsaci et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Anti-EGFR Monoclonal Antibodies for Treatment of Colorectal Cancers: Development of Cetuximab and Panitumumab
Benoit You et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis
Naresh Punwani et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
The secret ally: immunostimulation by anticancer drugs
Lorenzo Galluzzi et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The role of classical and non-classical HLA class I antigens in human tumors
Juergen Bukur et al.
SEMINARS IN CANCER BIOLOGY (2012)
FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer
K. Tamura et al.
ANNALS OF ONCOLOGY (2011)
Inhibition of poxvirus spreading by the anti-tumor drug Gefitinib (Iressa (TM))
Stefan Langhammer et al.
ANTIVIRAL RESEARCH (2011)
Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes
Michael S. Leibowitz et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes
Brian P. Pollack et al.
CLINICAL CANCER RESEARCH (2011)
Kinase inhibitors in the treatment of chronic hepatitis C virus
E. Bardou-Jacquet et al.
GUT (2011)
Preclinical Evaluation of Local JAK1 and JAK2 Inhibition in Cutaneous Inflammation
Jordan S. Fridman et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
Off-Target Serine/Threonine Kinase 10 Inhibition by Erlotinib Enhances Lymphocytic Activity Leading to Severe Skin Disorders
Naoko Yamamoto et al.
MOLECULAR PHARMACOLOGY (2011)
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy
Joachim Lupberger et al.
NATURE MEDICINE (2011)
Targeting the human EGFR family in esophagogastric cancer
Alicia Okines et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
John M. L. Ebos et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Towards a systems understanding of MHC class I and MHC class II antigen presentation
Jacques Neefjes et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
Andrea Boni et al.
CANCER RESEARCH (2010)
Inflammatory cytokines as a third signal for T cell activation
Julie M. Curtsinger et al.
CURRENT OPINION IN IMMUNOLOGY (2010)
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib
Emma Guttman-Yassky et al.
EUROPEAN JOURNAL OF CANCER (2010)
Colorectal cancer in review: the role of the EGFR pathway
Muhammad W. Saif
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Tumor Antigen-Targeted, Monoclonal Antibody-Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape
Robert L. Ferris et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage
Tanja Schneider-Merck et al.
JOURNAL OF IMMUNOLOGY (2010)
Lambda Interferon Renders Epithelial Cells of the Respiratory and Gastrointestinal Tracts Resistant to Viral Infections
Markus Mordstein et al.
JOURNAL OF VIROLOGY (2010)
Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6
Melodie L. Weller et al.
NATURE MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The role of signaling pathways in the development and treatment of hepatocellular carcinoma
S. Whittaker et al.
ONCOGENE (2010)
The Epidermal Growth Factor Receptor (EGFR) Promotes Uptake of Influenza A Viruses (IAV) into Host Cells
Thorsten Eierhoff et al.
PLOS PATHOGENS (2010)
Respiratory virus induction of alpha-, beta- and lambda-interferons in bronchial epithelial cells and peripheral blood mononuclear cells
M. R. Khaitov et al.
ALLERGY (2009)
Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells
Andres Lopez-Albaitero et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies
Junko Ozao-Choy et al.
CANCER RESEARCH (2009)
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
Jennifer S. Ko et al.
CLINICAL CANCER RESEARCH (2009)
Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
Frederic Bibeau et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Ultraviolet B Radiation Generated Platelet-Activating Factor Receptor Agonist Formation Involves EGF-R-Mediated Reactive Oxygen Species
Yongxue Yao et al.
JOURNAL OF IMMUNOLOGY (2009)
Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX
Andrew W. Pawluczkowycz et al.
JOURNAL OF IMMUNOLOGY (2009)
Maturation Pathways of Dendritic Cells Determine TAP1 and TAP2 Levels and Cross-presenting Function
Andres Lopez-Abaitero et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Immunotherapy of Head and Neck Cancer Using Tumor Antigen-Specific Monoclonal Antibodies
Steve C. Lee et al.
CURRENT ONCOLOGY REPORTS (2009)
Myeloid-Derived Suppressor Cells: A Novel Therapeutic Target
Jennifer S. Ko et al.
CURRENT ONCOLOGY REPORTS (2009)
Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors
Ann Marie Egloff et al.
JOURNAL OF ONCOLOGY (2009)
MHC class I antigen presentation: learning from viral evasion strategies
Ted H. Hansen et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Risk of hand-foot skin reaction with sorafenibo: A systematic review and metes-analysis
David Chu et al.
ACTA ONCOLOGICA (2008)
Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma
Anne F. Buckley et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
Madeleine M. Hipp et al.
BLOOD (2008)
Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies
Michael Dechant et al.
CANCER RESEARCH (2008)
Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
James H. Finke et al.
CLINICAL CANCER RESEARCH (2008)
Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation
Ninke Leffers et al.
GYNECOLOGIC ONCOLOGY (2008)
Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression
Inge S. van Houdt et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer
Vincenzo Pitini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Epidermal growth factor treatment decreases mortality and is associated with improved gut integrity in sepsis
Jessica A. Clark et al.
SHOCK (2008)
Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib
S. E. Rosenbaum et al.
SUPPORTIVE CARE IN CANCER (2008)
Gastrointestinal complications of oncologic therapy
Marta Davila et al.
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY (2008)
Immunity, ageing and cancer
Evelyna Derhovanessian et al.
Immunity & Ageing (2008)
VEGF-targeted therapy: mechanisms of anti-tumour activity
Lee M. Ellis et al.
NATURE REVIEWS CANCER (2008)
The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor-positive tumor cells is enhanced by cytokines
Julie M. Roda et al.
CLINICAL CANCER RESEARCH (2007)
FCGR2A and FCGR3A Polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab
Wu Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non-small-cell lung cancer
Geoffrey Chan et al.
BLOOD (2007)
Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis
Brooke Ancrile et al.
GENES & DEVELOPMENT (2007)
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies
Bret Wacker et al.
CLINICAL CANCER RESEARCH (2007)
Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer
W. Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Inhibiting epidermal growth factor receptor improves structural, locomotor, sensory, and bladder recovery from experimental spinal cord injury
Matthias Erschbamer et al.
JOURNAL OF NEUROSCIENCE (2007)
The kinase inhibitor imatinib - An immunosuppressive drug?
D. Wolf et al.
CURRENT CANCER DRUG TARGETS (2007)
Cancer immunologists and cancer biologists: Why we didn't talk then but need to now
George C. Prendergast et al.
CANCER RESEARCH (2007)
Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management
Thomas J. Lynch et al.
ONCOLOGIST (2007)
Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing
Jon A. Weidanz et al.
JOURNAL OF IMMUNOLOGY (2006)
The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells
Hidetoshi Sumimoto et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Immune suppression in the tumor microenvironment
TF Gajewski et al.
JOURNAL OF IMMUNOTHERAPY (2006)
EGFR activation mediates inhibition of axon regeneration by myelin and chondroitin sulfate proteoglycans
V Koprivica et al.
SCIENCE (2005)
Cutaneous adverse effects with HER1/EGFR-targeted agents:: Is there a silver lining?
R Peréz-Soler et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Chemoprevention of UV light-induced skin tumorigenesis by inhibition of the epidermal growth factor receptor
TB El-Abaseri et al.
CANCER RESEARCH (2005)
T cell receptor binding kinetics required for T cell activation depend on the density of cognate ligand on the antigen-presenting cell
PA González et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
KY Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Human leukocyte antigen (HLA) class I defects in head and neck cancer
RL Ferris et al.
IMMUNOLOGIC RESEARCH (2005)
Modeling the cancer patient with genetically engineered mice: Prediction of toxicity from molecule-targeted therapies
RB Roberts et al.
CANCER CELL (2004)
Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo
AB Dietz et al.
BLOOD (2004)
Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro
K Cwynarski et al.
LEUKEMIA (2004)
Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis
A Sparmann et al.
CANCER CELL (2004)
HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway
F Herrmann et al.
CANCER RESEARCH (2004)
Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus
X Wang et al.
NATURE (2003)
Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation
F Mascia et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression
JE Ohm et al.
BLOOD (2003)
Transcriptional regulation of the MHC class II antigen presentation pathway
JM Boss et al.
CURRENT OPINION IN IMMUNOLOGY (2003)
The role of heregulin-α as a motility factor and amphiregulin as a growth factor in wound healing
VRJ Schelfhout et al.
JOURNAL OF PATHOLOGY (2002)
MHC class I negative phenotype of disseminated tumor cells in bone marrow is associated with poor survival in R0M0 breast cancer patients
A Zia et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Antigen-processing machinery breakdown and tumor growth
B Seliger et al.
IMMUNOLOGY TODAY (2000)
分享论文
